No abstract

Effective vaccines are vital to the fight against the COVID-19 global pandemic. As a critical component of a subunit vaccine, the adjuvant is responsible for strengthening the antigen-induced immune responses. Here, we present a new nanovaccine that comprising the Receptor-Binding Domain (RBD) of spike protein and the manganese nanoadjuvant (MnARK), which induces humoral and cellular responses. Notably, even at a 5-fold lower antigen dose and with fewer injections, mice immunized with the MnARK vaccine immunized mice showed stronger neutralizing abilities against the infection of the pseudovirus (~270-fold) and live coronavirus (>8-fold) in vitro than that of Alum-adsorbed RBD vaccine (Alu-RBD). Furthermore, we found that the effective co-delivery of RBD antigen and MnARK to lymph nodes (LNs) elicited an increased cellular internalization and the activation of immune cells, including DC cells, CD4 + and CD8 + T lymphocytes. Our findings highlight the importance of MnARK adjuvant in the design of novel coronavirus vaccines and provide a rationale strategy to design protective vaccines through promoting cellular internalization and the activation of immune-related pathways.

Cotton verticillium wilt (Verticillium dahliae Kleb.) is a very destructive disease. In this study, we evaluated a Bacillus subtilis enhanced bio-organic fertilizer (BOF) for control of the disease and for its eff ect on rhizosphere microbiota. Greenhouse pot experiments were conducted during three cotton (Gossypium hirsutum L.) growing seasons with serial treatments of BOF or unenhanced organic fertilizer (OF). Consistent control of cotton verticillium wilt was obtained in the three trials. Th e complete BOF treatment, in which both nursery cups with healthy soils and transplanted pots with diseased soils were amended with BOF, was the most eff ective in reducing the counts of pathogenic V. dahliae and of total fungi in the cotton rhizosphere. Th e complete BOF treatment was also the most eff ective in reducing disease incidence. Rhizosphere soil DNA was extracted at harvest and the 5´ end (370 base pairs) of the fungal 18S rRNA gene was amplifi ed by using the primer pair NS1 and GCFung (fungus specifi c). Seventy-one bands were recognized in denaturing gradient gel electrophoresis (DGGE) gels and excised for sequencing, but only 35 bands were successfully sequenced during the study. Nonmetric multidimensional scaling analysis of DGGE patterns showed that the complete BOF treatments were not close to any other treatment. Ribotypes related to four Ascomycota and two Basidiomycota fungi were detected in the untreated but not in the BOF-amended soil. Th e results suggest that the complete BOF treatment could eff ectively control cotton verticillium wilt by signifi cantly improving fungal structure in rhizosphere soils.

Enterovirus A71 (EV-A71) inactivated vaccines have been widely inoculated among children in Kunming City after it was approved. However, there was a large-scale outbreak of Enteroviruses (EVs) infection in Kunming, 2018.The epidemiological characteristics of HFMD and EVs were analyzed during 2008 to 2018, which are before and three years after EV-A71 vaccine starting to use. The changes of infection spectrum were also investigated, especially for severe HFMD in 2018.The incidence of EV-A71 decreased dramatically after EV-A71 vaccine starting use. The proportion of non CV-A16/EV-A71 EVs positive patients raised up to 77.17% to 85.82%, while, EV-A71 and CV-A16 only accounted for 3.41% to 7.24% and 6.94% to 19.42% in 2017 and 2018. CV-A6 was the most important causative agent in all clinical symptoms (Severe HFMD, HFMD, Herpangina and fever), accounting from 42.13% to 62.33%. EV-A71 only account for 0.36% to 2.05%. In sever HFMD, CV-A6 (62.33%), CV-A10 (11.64%), CV-A16 (10.96%) were the major causative agent in 2018. EV-A71 inactivated vaccine has a good protective effect against EV-A71 and induced EVs infection spectrum changefully. EV-A71 vaccine has no or insignificant cross-protection effect on CV-A6, CV-A10 and CV-A16. Herein, developing 4-valent combined vaccines is urgently needed.